| First Author | Fang L | Year | 2022 |
| Journal | Cancer Gene Ther | Volume | 29 |
| Issue | 10 | Pages | 1463-1476 |
| PubMed ID | 35393570 | Mgi Jnum | J:349055 |
| Mgi Id | MGI:7646020 | Doi | 10.1038/s41417-022-00454-5 |
| Citation | Fang L, et al. (2022) TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence. Cancer Gene Ther 29(10):1463-1476 |
| abstractText | ERG translocations are commonly involved in the initiation of prostate neoplasia, yet previous experimental approaches have not addressed mechanisms of oncogenic inception. Here, in a genetically engineered mouse model, combining TMPRSS2-driven ERG with Kras(G12D) led to invasive prostate adenocarcinomas, while ERG or Kras(G12D) alone were non-oncogenic. In primary prostate luminal epithelial cells, following inducible oncogenic Kras expression or Pten depletion, TMPRSS2-ERG suppressed oncogene-induced senescence, independent of TP53 induction and RB1 inhibition. Oncogenic KRAS and TMPRSS2-ERG synergized to promote tumorigenesis and metastasis of primary luminal cells. The presence of TMPRSS2-ERG compared to a wild-type background was associated with a stemness phenotype and with relatively increased RAS-induced differential gene expression for MYC and mTOR-regulated pathways, including protein translation and lipogenesis. In addition, mTOR inhibitors abrogated ERG-dependent senescence resistance. These studies reveal a previously unappreciated function whereby ERG expression primes preneoplastic cells for the accumulation of additional gene mutations by suppression of oncogene-induced senescence. |
